PRL and hyperprolactinemia: Cariprazine displayed favourable effects on metabolic and hormonal parameters; causing modest weight loss in 5/8 patients (2–6kg, mean change in BMI -3.1), and reducing prolactin levels in all patients (where levels were available, mean change -732mIU/L), as well as resolving symptomatic hyperprolactinaemia associated with previous antipsychotic exposure in 3/8 patients.